For the quarter ended December 2024, BioCryst Pharmaceuticals (BCRX) reported revenue of $131.53 million, up 40.8% over the same period last year. EPS came in at -$0.13, compared to -$0.28 in the year-ago quarter.The reported revenue represents a surprise of +0.56% over the Zacks Consensus Estimate of $130.8 million. With the consensus EPS estimate being -$0.06, the EPS surprise was -116.67%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they comp ...

Core Viewpoint - BioCryst Pharmaceuticals (BCRX) has experienced a decline of 11.5% over the past week, but the formation of a hammer chart pattern suggests potential support and a possible trend reversal in the future [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottoming out, suggesting that selling pressure may be exhausting [2][4]. - A hammer pattern forms when there is a small candle body with a long lower wick, typically occurring during a downtrend, signaling that bears may be losing control [3][4]. - This pattern can appear on various timeframes and is utilized by both short-term and long-term investors [4]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for BCRX, which is a bullish indicator for the stock [6]. - The consensus EPS estimate for the current year has increased by 18.4% over the last 30 days, indicating that analysts expect better earnings than previously predicted [7]. - BCRX holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [8].

BioCryst Pharmaceuticals (BCRX) closed the last trading session at $8.28, gaining 4.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.25 indicates an 84.2% upside potential.The average comprises 12 short-term price targets ranging from a low of $8 to a high of $30, with a standard deviation of $6.48. While the lowest estimate indicates a decline of 3.4% from the current price ...

Group 1 - The biotech sector has experienced significant volatility, with investors often focusing on hyped plays rather than long-term winners [1] - BioCryst Pharmaceuticals is highlighted as a strong player in the rare disease market that has not yet received adequate market recognition [1] - The approach to investment in high-growth companies involves a combination of fundamental analysis and future trend prediction, emphasizing the potential of innovation for substantial returns [1]

After working as a Registered Nurse for several years, I transitioned into financial analysis, earning my MBA and developing expertise in healthcare & technology investments. Since 2017, I've published investment analyses on Seeking Alpha, focusing on thorough valuation modeling. My approach centers on examining core assumptions that drive stock valuations, particularly through detailed discounted cash flow analysis. I provide readers with various scenarios to help them understand potential outcomes. The pr ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Back in November 2023, I published a note on BioCryst (NASDAQ: BCRX ) to Seeking Alpha, assigning its stock a "Sell" rating. At the time, shares were priced at $5.5, and in ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdict ...

Investors clearly weren't in a forgiving mood on Monday when it came to BioCryst Pharmaceuticals (BCRX -9.99%) stock. After the commercial-stage biotech published its fourth-quarter and full-year 2024 results, they traded its shares down by an even 10% on the day. That fall was far steeper than the 0.5% slip of the benchmark S&P 500 (^GSPC -0.50%).A mixed final quarter of 2024For the quarter, BioCryst managed to increase its revenue by 41% to $131.5 million. The company also narrowed its generally accepted ...

Fourth Quarter 2024 Results Call Corporate Update & Financial Results February 24, 2025 CONFIDENTIAL & PROPRIETARY Forward-looking statements BioCryst's presentation contains forward-looking statements, including, but not limited to, statements regarding future results and forward-looking financial information, company performance, achievements, future market share or size, and expectations regarding pipeline development. These statements are subject to known and unknown risks, uncertainties and other facto ...

Financial Data and Key Metrics Changes - For Q4 2024, total revenue was $131.5 million, with Orladeo contributing $124.2 million [39] - Full year 2024 total revenue reached $450.7 million, with Orladeo accounting for $437.7 million [39] - Non-GAAP operating profit was $62.9 million, a significant increase from a non-GAAP operating loss of $48.1 million in 2023 [40] - Cash at the end of 2024 was approximately $343 million, with net cash utilization for Q4 at $8.4 million [41] Business Line Data and Key Metrics Changes - Orladeo revenue grew by 34% year-over-year, maintaining the same number of new patients as in its first year [9] - For Q4, $17.2 million (13.9%) of Orladeo's revenue came from ex-US markets, while for the full year, it was $51.7 million (11.8%) [39] - The company raised Orladeo revenue guidance for 2025 to between $535 million and $550 million [14] Market Data and Key Metrics Changes - 97% of surveyed US HAE treaters are considering prescribing Orladeo, with 59% extremely likely to prescribe it to more patients [17] - The company noted a significant increase in the percentage of Medicare patients able to afford co-payments due to the Inflation Reduction Act [13] Company Strategy and Development Direction - The company aims to file an NDA for Orladeo for pediatric use in children aged 2 to 11 this year [21] - BCX1775 for Netherton syndrome and Avoralstat for diabetic macular edema are advancing in clinical trials, with expectations for meaningful data readouts this year [21][28] - Long-term revenue guidance includes a three-year CAGR of 20%, targeting over $750 million by 2027 and $1 billion by 2029 [44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the execution and performance across the company, highlighting a strong position for future growth [8] - The management team noted that the execution in 2024 has set the stage for positive and sustainable cash flow and EPS in the second half of 2025 [43] - There is optimism regarding the potential for BCX1775 to address an unmet need in Netherton syndrome, which is currently underdiagnosed [27] Other Important Information - The company is seeing strong commercial demand for RAPIVAB due to the prevalence of flu, despite some uncertainty around future government funding [42] - The pediatric oral granule formulation of Orladeo has shown promising results in trials, with high tolerability and retention rates [35][114] Q&A Session Summary Question: Can you narrow down when data from Netherton patients is expected? - Management indicated that data will be available later this year, with a focus on skin healing and KLK5 activity [51][52] Question: What is the current paid patient proportion for Orladeo? - The company reported a 73.5% paid rate across all patients, with about 20% of patients on Medicare [120] Question: How does the pediatric study's tolerability compare to adults? - The pediatric oral granules have shown good tolerability and compliance, similar to adult experiences [98] Question: What is the expected timeline for dosing Netherton syndrome patients? - Dosing for Netherton syndrome patients is expected to begin around mid-year, with data on skin activity anticipated by year-end [83] Question: What percentage of KLK5 suppression is needed for clinical benefit? - The company is looking for nearly complete suppression of KLK5 activity, although the exact percentage required for clinical benefit is not yet known [128]